Holders — by stockHoldings — by fund
Privium Fund Management B.V.
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 1795097
$544.2M
disclosed book value
61
positions
17.6%
largest position share
Positions, as of 2026-06-30
top 61 of 61 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | TSLATESLA INC | 228,000 | $95.9M | 17.6% |
| 2 | SHOPSHOPIFY INC | 370,000 | $42.2M | 7.8% |
| 3 | AMDADVANCED MICRO DEVICES INC | 62,000 | $36.0M | 6.6% |
| 4 | AMZNAMAZON COM INC | 140,000 | $33.4M | 6.1% |
| 5 | IONSIONIS PHARMACEUTICALS INC | 319,924 | $25.4M | 4.7% |
| 6 | SPOTIFY TECHNOLOGY S A | 55,000 | $25.3M | 4.6% |
| 7 | PLTRPALANTIR TECHNOLOGIES INC | 200,000 | $23.3M | 4.3% |
| 8 | ARWRARROWHEAD PHARMACEUTICALS IN | 234,222 | $19.1M | 3.5% |
| 9 | OPENOPENDOOR TECHNOLOGIES INC | 3.9M | $18.2M | 3.3% |
| 10 | LMNDLEMONADE INC | 270,259 | $17.6M | 3.2% |
| 11 | NVDANVIDIA CORPORATION | 81,000 | $16.2M | 3% |
| 12 | IREN LIMITED | 340,150 | $15.6M | 2.9% |
| 13 | UNIQURE NV | 328,322 | $15.1M | 2.8% |
| 14 | CEREBRAS SYSTEMS INC | 60,500 | $13.4M | 2.5% |
| 15 | ASTSAST SPACEMOBILE INC | 145,000 | $12.9M | 2.4% |
| 16 | RAREULTRAGENYX PHARMACEUTICAL IN | 338,800 | $11.3M | 2.1% |
| 17 | ARQTARCUTIS BIOTHERAPEUTICS INC | 399,367 | $10.5M | 1.9% |
| 18 | BIIBBIOGEN INC | 48,400 | $10.5M | 1.9% |
| 19 | PROQR THRAPEUTICS N V | 5.5M | $10.3M | 1.9% |
| 20 | AXSMAXSOME THERAPEUTICS INC. | 39,944 | $9.8M | 1.8% |
| 21 | UROGEN PHARMA LTD | 210,000 | $7.7M | 1.4% |
| 22 | SPCXSPACE EXPLORATION TECHN CORP | 40,000 | $6.8M | 1.3% |
| 23 | DNLIDENALI THERAPEUTICS INC | 229,857 | $5.9M | 1.1% |
| 24 | VRTXVERTEX PHARMACEUTICALS INC | 9,400 | $4.7M | 0.9% |
| 25 | BMRNBIOMARIN PHARMACEUTICAL INC | 75,000 | $4.3M | 0.8% |
| 26 | KRYSKRYSTAL BIOTECH INC | 11,170 | $4.2M | 0.8% |
| 27 | ALNYALNYLAM PHARMACEUTICALS INC | 11,372 | $3.4M | 0.6% |
| 28 | VRDNVIRIDIAN THERAPEUTICS INC | 173,516 | $3.2M | 0.6% |
| 29 | BNTXBIONTECH SE | 30,100 | $2.8M | 0.5% |
| 30 | HIMSHIMS & HERS HEALTH INC | 80,000 | $2.8M | 0.5% |
| 31 | MEIRAGTX HLDGS PLC | 196,112 | $2.6M | 0.5% |
| 32 | ABEVAMBEV SA | 802,167 | $2.5M | 0.5% |
| 33 | SRPTSAREPTA THERAPEUTICS INC | 136,500 | $2.5M | 0.5% |
| 34 | CRISPR THERAPEUTICS AG | 44,974 | $2.5M | 0.5% |
| 35 | BEAMBEAM THERAPEUTICS INC | 70,282 | $2.4M | 0.4% |
| 36 | ZLABZAI LAB LTD | 122,189 | $2.3M | 0.4% |
| 37 | MRNAMODERNA INC | 29,994 | $2.1M | 0.4% |
| 38 | CARTESIAN THERAPEUTICS INC | 151,675 | $1.6M | 0.3% |
| 39 | MAGNUM ICE CREAM CO NV | 98,221 | $1.5M | 0.3% |
| 40 | WAVE LIFE SCIENCES LTD | 241,010 | $1.4M | 0.3% |
| 41 | TSHATAYSHA GENE THERAPIES INC | 198,900 | $1.4M | 0.2% |
| 42 | ZTSZOETIS INC | 17,322 | $1.2M | 0.2% |
| 43 | 4D MOLECULAR THERAPEUTICS IN | 90,110 | $1.2M | 0.2% |
| 44 | FATE THERAPEUTICS INC | 414,311 | $1.1M | 0.2% |
| 45 | LEGNLEGEND BIOTECH CORP | 35,400 | $1.0M | 0.2% |
| 46 | ROCKET PHARMACEUTICALS INC | 244,146 | $834,979 | 0.2% |
| 47 | NOVNOV INC | 42,026 | $779,582 | 0.1% |
| 48 | BTGB2GOLD CORP | 195,083 | $729,610 | 0.1% |
| 49 | TOTALENERGIES SE | 10,723 | $729,486 | 0.1% |
| 50 | LEXEO THERAPEUTICS INC | 155,000 | $722,300 | 0.1% |
| 51 | TRANSOCEAN LTD | 145,604 | $712,004 | 0.1% |
| 52 | MOHMOLINA HEALTHCARE INC | 2,979 | $681,297 | 0.1% |
| 53 | NU HLDGS LTD | 44,000 | $587,840 | 0.1% |
| 54 | AUTOLUS THERAPEUTICS LTD | 363,430 | $581,488 | 0.1% |
| 55 | TDWTIDEWATER INC NEW | 8,683 | $578,548 | 0.1% |
| 56 | LULULULULEMON ATHLETICA INC | 5,063 | $578,093 | 0.1% |
| 57 | SANDRIDGE ENERGY INC | 38,792 | $531,450 | 0.1% |
| 58 | SEABRIDGE GOLD INC | 16,512 | $425,019 | 0.1% |
| 59 | VOYAGER THERAPEUTICS INC | 120,000 | $420,000 | 0.1% |
| 60 | ENGENE THERAPEUTICS INC | 170,000 | $294,100 | 0.1% |
| 61 | COSAN S A | 52,000 | $149,760 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.